Day: November 28, 2023

Nov 28

Rise of the Indian Challengers in the Global Cardiovascular Devices Market

<!– –> Rise of the Indian Challengers in the Global Cardiovascular Devices Market, ET HealthWorld <!– –> <!– –> <!– We have updated our terms and conditions and privacy policy Click “Continue” to accept and continue with ET HealthWorld –> <!– X We use cookies to ensure best experience for you We use cookies and other tracking technologies to improve your browsing experience on our site, show personalize content and targeted ads, analyze site traffic, and understand where our audience is coming from. You can also read our privacy policy, We use cookies to ensure the best experience for you on our website. By choosing I accept, or by continuing being on the website, you consent to our use of Cookies and Terms & Conditions. Analytics and Performance Cookies Targeted and Advertising Cookies –> <!– skip to main content –> <section class="container article-section status_prime_article single-post currentlyInViewport inViewPort" id="news_dtl_105572044" data-article="0" page-title="Rise of the Indian Challengers in the Global Cardiovascular Devices Market" data-href="https://health.economictimes.indiatimes.com/news/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market/105572044" data-msid="105572044" data-news="{"link":"/news/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market/105572044","seolocation":"/news/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market/105572044","seolocationalt":"/news/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market/105572044","seometatitle":false,"seo_meta_description":"The Indian domestic market is now poised for much faster growth compared to its global peers due to its considerably small base versus the size of its population. Deepening insurance penetration, rising affordability and the widening of patient pool driven by government sponsored schemes are some of the key factors driving this growth. ","canonical_url":false,"url_seo":"/news/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market/105572044","category_name":"Medical Devices","category_link":"/news/medical-devices","category_name_seo":"medical-devices","updated_at":"2023-11-29 05:58:33","artexpdate":false,"agency_name":"ETHealthWorld","agency_link":"/agency/88675629/ETHealthWorld","read_duration":"4 min","no_index_no_follow":false,"keywords":[{"id":1832783,"name":"ujjwal singh","type":"General","weightage":80,"keywordseo":"ujjwal-singh","botkeyword":false,"source":"Orion","link":"/tag/ujjwal+singh"},{"id":3727552,"name":"meril life sciences","type":"General","weightage":80,"keywordseo":"meril-life-sciences","botkeyword":false,"source":"Orion","link":"/tag/meril+life+sciences"},{"id":1715229,"name":"smt","type":"General","weightage":50,"keywordseo":"smt","botkeyword":false,"source":"Orion","link":"/tag/smt"},{"id":53564,"name":"southeast asia","type":"General","weightage":50,"keywordseo":"southeast-asia","botkeyword":false,"source":"Orion","link":"/tag/southeast+asia"},{"id":15378315,"name":"Cardiovascular devices","type":"General","weightage":20,"keywordseo":"Cardiovascular-devices","botkeyword":false,"source":"Orion","link":"/tag/cardiovascular+devices"},{"id":1069791,"name":"translumina","type":"General","weightage":20,"keywordseo":"translumina","botkeyword":false,"source":"Orion","link":"/tag/translumina"},{"id":5949510,"name":"percutaneous coronary interventions","type":"General","weightage":20,"keywordseo":"percutaneous-coronary-interventions","botkeyword":false,"source":"Orion","link":"/tag/percutaneous+coronary+interventions"},{"id":1544318,"name":"stent implants","type":"General","weightage":20,"keywordseo":"stent-implants","botkeyword":false,"source":"Orion","link":"/tag/stent+implants"}],"read_industry_leader_count":false,"read_industry_leaders":false,"embeds":[{"title":"Over the last six years, most Indian stent manufacturers have seen exponential growth in international markets and have established a strong foothold in multiple countries.","type":"image","caption":false,"elements":[]}],"thumb_big":"https://etimg.etb2bimg.com/thumb/msid-105572044,imgsize-132670,width-1200,height=765,overlay-ethealth/medical-devices/rise-of-the-indian-challengers-in-the-global-cardiovascular-devices-market.jpg","thumb_small":"https://etimg.etb2bimg.com/thumb/img-size-132670/105572044.cms?width=150&height=112","time":"2023-11-29 05:58:12","is_live":false,"prime_id":0,"highlights":[],"highlights_html":"","also_read_available":false,"body":" by Ujjwal Singh The Indian Cardiovascular devices landscape witnessed a turning point in November 2018, when the Government of India notified price control on stents, bringing down the prices by more than 80%. With a current market size of ~USD 200 million, this market is slated to be one of the fastest growing in the world, growing at a staggering 14-15% CAGR over next decade. Let’s find out what’s driving this growth. A stent in timeHistorically speaking, it’s interesting to note that India’s medical devices market was dominated by global majors. This heavy reliance on expensive imported devices hindered accessibility to life-saving interventions, with only a fraction of the population receiving essential procedures, such as percutaneous coronary interventions (PCI). However, post implementation of the price cap, there was an over 30% surge in the number of stent implants in just 12 months. The price control combined with inclusion of stent implants in government schemes led to both a multi-fold increase in stent implants and a remarkable shift in the Indian landscape, with Indian players increasing their market share from 35% to an impressive 60%. Global majors such as Abbott Vascular, Boston Scientific, and Medtronic, had to adapt to the revised pricing, allowing local players, such as, SMT, Translumina, and Meril room to grow their share by providing high-quality products but at a much lower cost. India’s advantage in manufacturing, with low labour costs and a pool of skilled talent, further fuelled the growth of domestic production. The Indian domestic market is now poised for much faster growth compared to its global peers due to its considerably small base versus the size of its population. Deepening insurance penetration, rising affordability and the widening of patient pool driven by government sponsored schemes are some of the key factors driving this growth. Global exports are also likely to play a critical role for domestic medical devices manufacturers, particularly those with high quality standards and in-house capabilities. Expanding into global marketsThe pricing reforms coincided with two big milestones in the Indian stent space – the successful completion of first clinical trial in India by SMT Pvt. Ltd and the launch of the first bioabsorbable stent by Meril Life Sciences. These two episodes provided a perfect launch pad to succeed in the international markets via increased acceptability and reliability of Indian manufactured cardiology devices. This led to a successful expansion by select Indian manufacturers across global markets, including Europe, Southeast Asia, Africa and the Middle East. Strong growth, global expansion and, rising profitability led to increased interest from financial sponsors, including Private Equity investors. This enabled Indian players to build world-class R&D and manufacturing infrastructure, while maintaining the local cost advantage. With additional capital and capabilities, select Indian manufacturers have been able to conduct expensive global trials and establish techno-commercial teams to navigate the complex regulatory and marketing processes in developed markets. Over the last six years, most Indian stent manufacturers have seen exponential growth in international markets and have established a strong foothold in multiple countries. Next Opportunity: Foray into the Structural Heart Devices marketWhile Indian players enjoyed success in stents in both domestic as well as international markets, structural heart devices market is still a nascent play for most. In recent years, many of the global CVD leaders have been shifting their focus towards structural heart devices due to significantly higher sophistication and realization. While the global structural heart devices market stood at USD 5.6 billion in 2020 and is expected to grow at 13% over the next 5 years, India’s structural heart market stands at a mere USD 12.4 million and is projected to grow at a 31% CAGR due to a very low base. In India, the limited penetration can be attributed to factors like affordability, accessibility, and a shortage of specialists capable of conducting these complex procedures. Per our interaction with few leading clinicians, we understand that minimally invasive procedures for structural heart disease can cost up to INR 30 lakhs using MNC products and nearly half using products from Indian players. On top of this high treatment cost, this procedure is currently not reimbursed by any government schemes, thus making it out of reach for most Indians. The success of Indian players in the stent market provides an ideal thesis for their foray into the structural heart devices market. With established distribution networks in both domestic and global markets, Indian companies can leverage their strengths to introduce new products through organic development and/or strategic acquisitions. With

Nov 28

Findings challenge standard understanding of COVID-19 infection

Some viruses move between species. For example, SARS-CoV-2, the virus that causes COVID-19, can spill over from humans to mink, an agricultural species, and then spill back from mink to humans. Spill back is a concern because SARS-CoV-2 can mutate in the mink and come back to humans in a more virulent form. Both spill over and spill back of SARS-CoV-2 have been reported on mink farms in the United States and Europe. To address these issues, a research team at the University of California, Riverside, has now studied zoonosis — the interspecies transmission of pathogens — in mink and found that TMPRSS2, an enzyme critical for viral fusion entry of SARS-CoV-2 in humans, is not functional in mink. Left: Prue Talbot (left) is seen with Ann Song, Right: Ann Song. (UCR/Talbot Research Group) “We found mink lung cells are infected by the ‘endocytosis pathway,’ not the TMPRSS2 fusion pathway commonly observed in human cells,” said doctoral student Ann Song, first author of the research paper that appears in Frontiers in Microbiology. “Our findings show that SARS-CoV-2 entry is not the same in all mammals and emphasize the need for thorough investigations into viral entry mechanisms across different species.” Song explained that viral fusion occurs when the membrane of the virus fuses with the plasma membrane of the host cell during infection. She said endocytosis is an essential process in which cells engulf external materials in small vesicles formed from their plasma membranes. SARS-CoV-2 can be taken up by host cells via endocytosis, she said. “Our results show that the functional — or enzymatic — domain is missing in mink TMPRSS2,” she said. “We do not know why. We think the enzyme may have multiple functions. It can do something else in mink, but it does not play a role in SARS-CoV-2 fusion to host cells. As a result, targeting TMPRSS2 would not be helpful in preventing infection in mink. What is clear is that SARS-CoV-2 entry varies among different species and tissue types.” Song said zoonosis is a public health concern as dangerous mutated forms of the virus could be introduced into the human population through spillback. During the pandemic, hundreds of papers were published on COVID-19 in humans. Now that COVID-19 in humans is under better control, scientific attention is turning to zoonosis. Lead author Prue Talbot, a professor of the graduate division in the Department of Molecular, Cell and Systems Biology in whose lab Song works, said researchers should not underestimate the possibility of spillover and spillback of SARS-CoV-2 in other mammalian species. “Deadly mutants can emerge from spillover/spillback events,” Talbot said. “As another example, many herds of deer, which are hunted by humans, are infected with SARS-CoV-2 and are thus potential sources of spillback.” Talbot and Song were joined in the research by postdoctoral researcher Rattapol Phandthong. Next, the research team will work on the infectability of human embryos in pregnant women who have COVID-19. To achieve their results, the researchers conducted their experiments using lung epithelial cells from mink. The research was supported by the Tobacco-Related Disease Research Program of the University of California, California Institute for Regenerative Medicine, and UCR. The title of the paper is “Endocytosis inhibitors block SARS-CoV-2 pseudoparticle infection of mink lung epithelium.”

Nov 28

Phoenix officer donates blood less than a year after being shot on the job

PHOENIX — Less than a year ago, Phoenix Police Department Officer Morgan Bullis was receiving blood transfusions as part of her recovery after being shot on the job. On Tuesday, she took part in giving the gift of life that helped save her own. In March 2023, the officer was shot in the hip and suffered injuries to her face from shrapnel during an incident near 7th and Southern avenues. At the time of her injury, the 26-year-old officer had been with the Phoenix Police Department for less than a year. Several months of recovery went by and Officer Bullis returned to her job in July. Officer Bullis was among multiple first responders who sat in blood donation chairs Tuesday during a Vitalant event to kick off their holiday blood drive. “Every day, my fellow brothers and sisters face difficult and dangerous situations in the line of duty,” said Officer Bullis. “A strong blood supply can make the difference of living and being able to go home.” Police officers and firefighters were invited by Vitalant to roll up their sleeves at the Hall of Flame museum. Vitalant representatives say every day, over 600 blood donors are needed to meet the needs of our state’s hospitals. ”We’re getting ready to enter our toughest week of the year for blood supply, basically the week between Christmas and New Years,” said Sue Thew with Vitalant. You can find out how to give blood through Vitalant by clicking here. Those who donate blood from Dec. 1-10 will receive a voucher for a complimentary admission to the Hall of Flame Fire Museum. You can also get a $10 gift card when you donate through Dec. 17.

Nov 28

On Giving Tuesday, Red Cross gives thanks to area blood donors

On Giving Tuesday, Red Cross gives thanks to area blood donors – CBS Chicago Watch CBS News The Red Cross needs to collect about 1,200 donations in the Chicago area. It opened two new permanent facilities in Schaumburg and Orland Park. CBS 2’s Irika Sargent found donors rolling up their sleeves – over and over again. View CBS News In Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On

Nov 28

Sign up now to donate blood with the Hopewell Township Health Department on December 7th

Help us strengthen our community this holiday season! The Hopewell Township Health Department is partnering with Miller-Keystone Blood Center on December 7, 2023, to hold our first annual blood drive. Registration is available online at https://donor.giveapint.org/donor/schedules/drive_schedule/87109 (or scan the QR code on the flyer). Blood donated through MKBC remains here in our local community to be used in the treatment of cancer patients, accident victims, premature babies, surgery and transplant patients, and others in need of lifesaving blood transfusions. Blood donation is a noble act, no matter where you do it. But when you give through Miller-Keystone, you are doing more to help your family, your friends, and your neighbors by helping to ensure that the blood needs of our regional hospitals are met. Blood donation truly is the gift of life. Please contact Public Health Nurse Debbie Flanders at 609-537-0238 or [email protected] with any questions.

Nov 28

Flu vaccine reduces risk for heart attack, cardiovascular death

November 29, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> Subscribe Added to email alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Key takeaways: Influenza vaccination was associated with a 20% reduced risk for cardiovascular death. Researchers said providers should target patients with CVD for vaccination to mitigate risks. Influenza vaccination was linked to significant decreased risks for major cardiovascular events and death, according to a study published in Scientific Reports. “Differing viewpoints exist regarding the impact of influenza vaccination on CVDs,” Fatemeh Omidi, MD, an assistant professor in the department of cardiology at Shahid Beheshti University of Medical Sciences in Iran, and colleagues wrote. “While certain observational investigations suggest a favorable correlation between influenza vaccination and the reduction in occurrences of cardiovascular incidents like acute [myocardial infarction (MI)], contrasting epidemiological studies propose the limited efficacy of influenza vaccines.” The researchers said an updated and comprehensive review on the association between influenza vaccination and CVD outcomes is “imperative.” So, they conducted a systematic review and meta-analysis of five studies with 9,059 patients who were randomly assigned to receive either a standard intramuscular influenza vaccination (n = 4,529) or intramuscular placebo (n = 4,530). Overall, there were 517 cases of major cardiovascular events among patients who received influenza vaccination, compared with 621 cases among those who received placebo (RR = 0.7; 95% CI, 0.55-0.91). The analysis also revealed a risk reduction for MI (RR = 0.74; 95% CI, 0.56-0.97) and a 20% risk reduction for cardiovascular death events (RR = 0.67; 95% CI, 0.45-0.98) among vaccinated patients. Such findings “underscore the potential impact of influenza vaccination in safeguarding against adverse cardiovascular outcomes among vulnerable patient populations,” the researchers wrote. They highlighted several possible mechanisms behind the findings. For example, influenza infections can weaken the immune system and make it susceptible to secondary infections, which “can exacerbate cardiovascular conditions,” Omidi and colleagues wrote. “Influenza vaccination’s role in preventing these secondary infections may indirectly contribute to the reduction in CVDs,” they wrote. The researchers added that influenza infections likely cause systemic inflammation, which can contribute to the progression of CVDs and atherosclerosis. “By targeting patients with recent CVDs for influenza vaccination, health care providers have a potential opportunity to mitigate the risk of cardiovascular death in a cost-effective and widely available manner,” Omidi and colleagues wrote. “Influenza vaccination programs could be tailored to prioritize this high-risk group, thus potentially reducing the overall burden on health care systems and improving patient outcomes.” They concluded that further research is still needed “to elucidate the precise mechanisms driving this association and to explore the long-term impact of influenza vaccination on cardiovascular outcomes.” Read more about Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . <button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”> Subscribe Added to email alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio

Nov 28

Opinion | CDC Advisors’ Infection Control Guidance Leaves Us Unprotected

Ross is a nurse and co-president of a nurses’ union. Thomason is an industrial hygienist. Earlier this month, the CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC) voted unanimously to approve its draft infection control guidelines and send it to the CDC for review. This extremely influential document, which was last updated 16 years ago, will be referenced by hospitals and other healthcare facilities to set their infection control policies. However, we’re concerned that the draft offers minimal recommendations to the CDC, and even worse, incorrectly treats surgical masks as respiratory protection. This unscientific guidance puts the U.S. in a weak position to protect patients and staff from currently circulating viruses and will leave us behind the curve in battling future pandemics. One of the biggest issues is with the new “air” category for pathogen transmission. The category includes three levels of precautions based on the transmissibility of a respiratory pathogen: “routine,” “special,” or “extended.” The guidance states that “routine” air precautions — the lowest level — are to be used with “common, often endemic, respiratory pathogens that spread predominantly over short distances.” But any delineation of endemic versus pandemic pathogens is arbitrary because the transmission mode of an aerosol-transmissible pathogen remains the same, so protections should also remain the same. (Note the draft guidelines don’t refer to “pandemic pathogens”; the “special” guidelines refer to “new or emerging” respiratory pathogens for which “effective treatments aren’t available.”) At the “routine” level, HICPAC recommends that masks be worn – but the committee indicates that surgical masks can be used, and healthcare workers may “choose voluntarily” to wear a higher level of protection. At this “routine” level, HICPAC recommends that masks be worn — but they indicate that surgical masks can be used, and healthcare workers may “choose voluntarily” to wear a higher level of protection. Why is HICPAC suggesting that surgical masks offer sufficient respiratory protection? The FDA, the Occupational Safety and Health Administration, the National Institute for Occupational Safety and Health, and even the CDC have indicated that surgical masks do not offer respiratory protection, especially against aerosol particles. These masks are loose fitting and do not filter the air breathed in by the wearer. HICPAC’s “flexible” guidance will result in inadequate protection for healthcare workers. Follow the Science Nurses are scientists. We follow the precautionary principle, which means we do not wait for proof of harm before taking action to protect people’s health. In other words, we should use the highest level of protections when confronted with a novel virus, and ground these decisions in the evidence: numerous studies show that COVID is spread primarily via aerosol transmission. HICPAC members claim that this part of the guidance is written to be “pathogen agnostic,” and a second part on infection control protocols for individual pathogens — including viruses like COVID-19 — is expected to be completed next year. But approving the “pathogen agnostic” guidance leaves us unprotected. Part of the issue stems from the lack of frontline healthcare workers, unions, or patients on the committee. As a result, we are at risk. We feel betrayed by the institutions that are supposed to safeguard our health. HICPAC’s vote lets us know that nurses and other healthcare workers are expendable to our employers — despite the staffing crisis. The message to us: We are not heroes. We are disposable. Flashbacks to Early COVID “We’re following CDC guidance,” was the answer many registered nurses got in 2020 when we were given a surgical mask instead of an N95 respirator or told to reuse single-use disposable N95s, forcing nurses to risk their lives to care for patients. In April 2020, RNs at Providence Saint John’s Health Center in Santa Monica, California were suspended when they refused to go into COVID patient rooms without an N95. That same month, Celia Yap-Banago, RN, who worked in the cardiac telemetry unit at Research Medical Center in Kansas City, Missouri, died because she contracted COVID at work after her employer failed to screen a patient with active COVID symptoms and did not give her an N95. She had previously raised concerns about the lack of personal protective equipment (PPE) at her hospital. Her employer had allegedly moved PPE from all units to one floor of the hospital so it was not available on her unit, which was not “supposed to” have COVID patients. Back then, the CDC gave healthcare employers flexibility to conduct their own risk assessment. Employers were following the CDC’s crisis and contingency standards that said a surgical mask was acceptable. The result was an enormous number of avoidable COVID infections and tragic deaths among healthcare workers at a time when their care was so desperately needed. We Need Stronger Guidance The committee’s new recommendations propose to give employers the same kind of flexibility that we’ve seen lead to needless illness and death. The draft guidance lets employers decide whether to implement the recommendations based on their own risk assessment. If the CDC approves the draft, it will lead to unnecessary infections, deaths, and long-term health consequences from a wide range of pathogens, including COVID, influenza, and RSV. After nearly 4 years of living with the COVID pandemic, we have all learned hard lessons about PPE and how healthcare employers often focus on the bottom line rather than protecting healthcare workers and patients. What healthcare workers need is more protection, guided by clear and specific guidance for employers. The updated infection control guidance must follow the science. We urge the CDC to reject HICPAC’s guidelines and create a new draft. Input from a broad range of stakeholders must be included: frontline nurses, other healthcare workers who will be implementing the infection control guidance, healthcare worker unions, and experts in infection prevention, ventilation engineering, respiratory protection, and industrial hygienists who have previously been excluded and ignored in HICPAC’s process. It’s time to revise, and it’s time to get the science right. Jean Ross, RN, is a nurse and a president of National Nurses United, the largest union